Brokerages Set Sanofi (NASDAQ:SNY) Price Target at $53.00


Share on StockTwits

Sanofi (NASDAQ:SNY) has received a consensus rating of “Hold” from the ten research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $53.00.

A number of equities research analysts have weighed in on the stock. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a report on Wednesday, February 10th. Deutsche Bank Aktiengesellschaft started coverage on Sanofi in a report on Friday, January 15th. They set a “sell” rating on the stock. Barclays restated an “equal weight” rating on shares of Sanofi in a report on Tuesday. Finally, UBS Group restated a “buy” rating on shares of Sanofi in a report on Tuesday, January 19th.

NASDAQ SNY traded up $0.49 on Monday, reaching $50.46. The company’s stock had a trading volume of 4,509 shares, compared to its average volume of 2,575,668. Sanofi has a twelve month low of $42.80 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.38 and a current ratio of 1.85. The stock has a market cap of $127.06 billion, a PE ratio of 21.35, a PEG ratio of 1.90 and a beta of 0.55. The firm’s 50 day moving average is $47.96 and its two-hundred day moving average is $48.74.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, February 4th. The company reported $0.73 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.88 by ($0.15). Sanofi had a net margin of 14.49% and a return on equity of 24.77%. The business had revenue of $9.38 billion during the quarter, compared to analyst estimates of $9.39 billion. During the same period in the previous year, the company posted $1.34 earnings per share. Sanofi’s revenue was down 2.4% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post 3.49 EPS for the current fiscal year.

The firm also recently announced an annual dividend, which will be paid on Wednesday, May 26th. Stockholders of record on Tuesday, May 4th will be issued a $1.9061 dividend. This is an increase from Sanofi’s previous annual dividend of $1.21. The ex-dividend date of this dividend is Monday, May 3rd. This represents a dividend yield of 3.2%. Sanofi’s dividend payout ratio is currently 35.24%.

Several institutional investors and hedge funds have recently modified their holdings of SNY. Reby Advisors LLC acquired a new position in shares of Sanofi in the 4th quarter valued at about $35,000. Arkadios Wealth Advisors acquired a new position in shares of Sanofi in the 4th quarter valued at about $36,000. Charter Oak Capital Management LLC acquired a new position in shares of Sanofi in the 4th quarter valued at about $40,000. JJJ Advisors Inc. increased its holdings in shares of Sanofi by 193.8% in the 4th quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock valued at $41,000 after purchasing an additional 562 shares during the period. Finally, Accel Wealth Management acquired a new position in shares of Sanofi in the 4th quarter valued at about $43,000. Institutional investors own 6.93% of the company’s stock.

Sanofi Company Profile

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.

Featured Story: How does a security become overbought?

Analyst Recommendations for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.